Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma

This symposium took place on 7th October 2016 as a part of the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark

Chairpersons: Francesco D’Amore,1 Ruth Pettengell2
Speakers: Pieternella Lugtenburg,3 Ruth Pettengell,2 Pier Luigi Zinzani,4 Raul Cordoba5

1. Aarhus University Hospital, Aarhus, Denmark
2. St George’s, University of London, London, UK
3. Erasmus MC Cancer Institute, Rotterdam, Netherlands
4. Institute of Hematology “Lorenzo e Ariosto Seràgnoli”, University of Bologna, Bologna, Italy
5. University Hospital Fundacion Jimenez Diaz, Madrid, Spain

Disclosure: Prof Francesco D’Amore has received speaker’s honoraria, advisory boards, and research support from Servier/CTI; speaker’s honoraria and research support from Takeda; fees for advisory boards from Nanovector; and research support from Sanofi/Genzyme and Roche. Dr Ruth Pettengell has acted as a speaker for CTI, Gilead, Pfizer, Servier, Takeda, and TEVA. Dr Pieternella Lugtenburg has received research funding from Takeda, Servier, and Roche; has acted as an advisor for Roche, Servier, Takeda, Celgene, Genmab, and BMS; and has acted as a speaker for Servier. Prof Raul Cordoba has acted as an advisor or speaker for Pfizer, Janssen, Gilead, Roche, and Servier. Prof Pier Luigi Zinzani has acted as an advisor or speaker for Roche, Celgene, Servier, Gilead, Janssen, Takeda, Pfizer, Astellas, and TG Pharmaceuticals.
Acknowledgements: Writing assistance was provided by Karen Yee, PhD, of ApotheCom.
Support: The symposium and publication of this article was funded by Servier. The views and opinions expressed are those of the authors and not necessarily of Servier.
Citation: EMJ Oncol. 2016;4[1]:47-55.

Meeting Summary

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL) remains an unmet clinical need because of its poor prognosis and the lack of effective therapeutic options. He proceeded to introduce pixantrone, the first approved single-agent treatment for the management of aggressive NHL in the third or fourth lines. Dr Lugtenburg then outlined the current treatment landscape for diffuse large B cell lymphoma (DLBCL). Dr Pettengell presented clinical evidence from the PIX301 study, explaining the clinical evidence behind the regulatory approvals for the use of pixantrone in relapsed or refractory aggressive NHL as well as discussing the mechanism of action of pixantrone. Prof Zinzani discussed the use of pixantrone as a new therapeutic option in clinical practice, and was followed by Prof Cordoba, who presented two clinical cases of patients treated with pixantrone. The symposium concluded with a panel discussion.

Download (PDF, 134KB)

Comments are closed.